Quantum BioPharma announced that dosing of drug has completed in 90-day oral toxicity and toxicokinetic studies for Lucid-21-302 for Multiple Sclerosis. These studies were commissioned to provide data to support an IND application with the US FDA.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Completes Key Studies for MS Drug Lucid-MS
- Quantum BioPharma Pursues Legal Action Over Alleged Stock Manipulation
- Quantum Group files amended complaint against CIBC, RBC, others
- Quantum BioPharma Schedules Business Update Call for May 6, 2025
- Quantum BioPharma Appoints Kevin Malone to Combat Stock Manipulation